REGN Jul 2024 1120.000 call
| Previous Close | 2.5200 |
| Open | 2.5200 |
| Bid | 0.0000 |
| Ask | 4.8000 |
| Strike | 1,120.00 |
| Expire Date | 2024-07-12 |
| Day's Range | 2.5200 - 2.5200 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 3 |
Simply Wall St.Insiders At Regeneron Pharmaceuticals Sold US$26m In Stock, Alluding To Potential Weakness
The fact that multiple Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) insiders offloaded a considerable amount of...
ZacksRegeneron (REGN) Gets Positive CHMP Opinion for Lymphoma Drug
Regeneron (REGN) gets positive CHMP recommendation for odronextamab for the treatment of adults with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma.
GlobeNewswireOdronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Recommendation based on data from the Phase 1 and pivotal Phase 2 trials demonstrating robust and durable response rates in both relapsed/refractory follicular lymphoma and diffuse large B-cell lymphomaTARRYTOWN, N.Y., June 28, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization of odro
